MedDataX Logo

Angeliq Regulatory Post Marketing Surveillance

NCT01064453 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4078

Last updated 2013-11-19

No results posted yet for this study

Summary

Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA). This is non-interventional , prospective, multi-center study.Target number of patients is 4500.

Conditions

  • Postmenopausal Period
  • Osteoporosis, Postmenopausal

Interventions

DRUG

E2/DRSP (Angeliq, BAY86-4891)

Take one tablet daily, continuously

Sponsors & Collaborators

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • South Korea

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01064453 on ClinicalTrials.gov